Addressing complex targets with novel modes of action

We are developing novel drugs to cure lifethreatening diseases with a primary focus in oncology, inflammation and pandemics response.

We are interested in expanding our portfolio in inflammation and oncology. We are seeking for novel targets with ideally a crystal structure available, PDX and/or patient lines available and a lab stage assay. Prior demonstration of druggability is not mandatory.